Search for: [Abstract = "\(n = 114\) treated with various bDMARDs were included. To explore for the impact of different remission definitions on the number of PsA patients achieving remission and\/or low disease activity, the following composite scores were analyzed\: clinical disease activity index \(CDAI\), simplified disease activity index \(SDAI\), disease activity index for psoriatic arthritis \(DAPSA\), clinical DAPSA \(cDAPSA\), DAS28, very low disease activity \(VLDA\), and minimal disease activity \(MDA\). To assess sex\-related differences, both entire cohort and men and women subgroups were analyzed. Baseline variables associated with remission were examined using linear and logistic regression models. P\-value < 0.05 was considered significant. Results In RA patients treated with RTX, all analyzed disease activity scores and patientreported outcomes \(PROs\), improved significantly \(p < 0.01\) during the 5\-year follow\-up compared to baseline. The most substantial changes were observed in the second year of treatment and effect was maintained throughout the entire analyzed period, with DAS28 4.9 at baseline, 4.7 after 1 year, 3.6 after 2 years, 3.1 after 3 years, 2 after 4 years, 8, after 5 years 2.7. No significant differences in drug effectiveness were noted between patients naïve to and previously treated with bDMARDs, and between concomitant and non\-concomitant users of conventional syntheti"]
